Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03446911

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery: Exploring Safety and Immunological Proof of Principle.

Sponsor: Amsterdam UMC, location VUmc

Conditions NSCLC, Stage I

Interventions SABR SABR + pembrolizumab

Updated 7 times since 2018 Last updated: Feb 20, 2018 Started: Mar 31, 2018 Primary completion: May 31, 2020 Completion: May 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on NSCLC, Stage I, this trial is ongoing. The trial is conducted by Amsterdam UMC, location VUmc and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2022 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2021 — May 2022 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2020 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Jun 2020 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Mar 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amsterdam UMC, location VUmc

Data source: Amsterdam UMC, location VUmc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.